April 30 (Reuters) - AzurRx BioPharma Inc ::AZURRX BIOPHARMA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.AZURRX BIOPHARMA INC - INTENDS TO USE PROCEEDS FROM OFFERING FOR EXPENSES ASSOCIATED WITH AZURRX'S CONTINUING CLINICAL DEVELOPMENT & TESTING OF MS1819.
Full Article
Nov 1 (Reuters) - AzurRx Biopharma Inc :AzurRx Biopharma Inc files for mixed shelf offering of up to $10 million - SEC filing.
Full Article
Oct 20 (Reuters) - Azurrx Biopharma Inc ::Azurrx Biopharma and Mayoly Spindler announce MS1819-SD investigational medicinal product dossier (IMPD) submission.Azurrx Biopharma - IMPD submitted via European Medicines Agency clinical trial portal for approval prior to opening of clinical centers in France.
Full Article
Oct 11 (Reuters) - Azurrx Biopharma Inc :Azurrx biopharma inc files for stock shelf of upto $10 million - sec filing.
Full Article
Sept 27 (Reuters) - AzurRx Biopharma Inc :AzurRx Biopharma and Mayoly-Spindler announce positive MS1819-SD phase II data in exocrine pancreatic insufficiency (epi).AzurRx Biopharma Inc - no serious adverse events or notable mild to moderate events have been reported in open-label, ascending dose phase IIA trial.AzurRx Biopharma Inc - favorable trends were also observed on other evaluated endpoints.AzurRx Biopharma Inc - secondary efficacy endpoints are consistently aligning with CFA data and safety profile of MS1819-SD remains favorable.
Full Article
Aug 23 (Reuters) - Azurrx Biopharma Inc :Azurrx reaches 6th patient enrollment of Phase IIA trial of MS1819 for treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis.Azurrx Biopharma Inc- results on first six patients expected in September from phase IIA trial of MS1819.Azurrx Biopharma Inc- added additional clinical trial site to further support enrollment in study and other planned future studies.
Full Article
Aug 11 (Reuters) - Azurrx Biopharma Inc -:Azurrx Biopharma Inc - on August 7, 2017, Azurrx Biopharma, Inc entered into a sublicense agreement with Transchem, Inc. - sec filing.Azurrx Biopharma- transchem granted co exclusive license to patents,patent apps related to helicobacter pylori 5'-methylthioadenosine nucleosidase inhibitors.
Full Article
July 21 (Reuters) - Azurrx Biopharma Inc ::Azurrx Biopharma Inc files for offering of 5.9 million shares of common stock by the selling stockholders .
Full Article
Azurrx Biopharma Inc : Azurrx Biopharma Inc- on April 11 entered securities purchase agreement with Lincoln Park Capital Fund, LLC - sec filing .Azurrx Biopharma- pursuant to agreement, issued to lpc 12% senior secured original issue discount convertible debenture in principal amount of $1.0 million.
Full Article
AzurRx BioPharma Inc : Azurrx biopharma-mayoly spindler grants co marketing rights for recombinant lipase in various geographies, including exclusive rights for north america . Azurrx biopharma inc - initial study results from ms1819-sd phase ii study are expected in first half of 2017 . Azurrx biopharma inc - azurrx and laboratoires mayoly spindler are party to a joint research and development agreement .Azurrx biopharma and mayoly-spindler announce initiation of phase ii clinical trial of ms1819-sd for exocrine pancreatic insufficiency in chronic pancreatitis patients.
Full Article
Earnings vs. 
Estimates